Westfield Capital Management Co. LP Has $462,000 Holdings in Icon Plc $ICLR

Westfield Capital Management Co. LP cut its stake in shares of Icon Plc (NASDAQ:ICLR) by 99.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,534 shares of the medical research company’s stock after selling 393,820 shares during the period. Westfield Capital Management Co. LP’s holdings in Icon were worth $462,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Toth Financial Advisory Corp acquired a new position in shares of Icon during the fourth quarter worth $27,000. Ameriflex Group Inc. acquired a new position in shares of Icon during the third quarter worth $33,000. Johnson Financial Group Inc. acquired a new position in shares of Icon during the third quarter worth $71,000. Quadrant Capital Group LLC bought a new stake in shares of Icon in the third quarter worth $78,000. Finally, Geneos Wealth Management Inc. increased its holdings in Icon by 11.5% in the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 56 shares during the period. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Stock Performance

Shares of ICLR opened at $149.45 on Friday. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $12.07 billion, a P/E ratio of 24.26, a price-to-earnings-growth ratio of 10.13 and a beta of 1.26. The firm’s fifty day simple moving average is $117.51 and its two-hundred day simple moving average is $140.85. Icon Plc has a 12 month low of $66.57 and a 12 month high of $211.00.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, May 27th. The medical research company reported $2.21 EPS for the quarter. The business had revenue of $2.11 billion for the quarter. Icon had a net margin of 5.98% and a return on equity of 9.50%. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. As a group, analysts predict that Icon Plc will post 9.74 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Robert W. Baird set a $119.00 price objective on Icon in a report on Friday, February 13th. Rothschild & Co Redburn set a $100.00 price objective on Icon and gave the company a “neutral” rating in a report on Tuesday, February 17th. Zacks Research downgraded Icon from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. increased their price objective on Icon from $120.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, May 29th. Finally, Citigroup increased their price objective on Icon from $120.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, May 29th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $156.44.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.